Cointime

Clementia Pharmaceuticals

company

About

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders.

  • 11 - 50

Highlights

Total Funding Amount
$60M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$60M
Industries
Biopharma,Biotechnology,Medical
Founded date
Jan 1, 2010
Number Of Employee
11 - 50
Operating Status
Active

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.

Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$60M
Clementia Pharmaceuticals has raised a total of $60M in funding over 2 rounds. Their latest funding was raised on Jun 23, 2015 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 23, 2015 Series Unknown $60M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Clementia Pharmaceuticals is funded by 1 investors. UCB are the most recent investors.
Investor Name Lead Investor Funding Round
UCB — Series Unknown
Cointime
Chủ Đề
Công Ty